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Abstract
Introduction: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovitis that
progresses to destruction of cartilage and bone. Bone marrow (BM) cells have been shown to contribute to this
pathogenesis. In this study, we compared differentially expressed molecules in BM cells from RA and osteoarthritis
(OA) patients and analyzed abnormal regulatory networks to identify the role of BM cells in RA.
Methods: Gene expression profiles (GEPs) in BM-derived mononuclear cells from 9 RA and 10 OA patients were
obtained by DNA microarray. Up- and down-regulated genes were identified by comparing the GEPs from the
two patient groups. Bioinformatics was performed by Expression Analysis Systemic Explorer (EASE) 2.0 based on
gene ontology, followed by network pathway analysis with Ingenuity Pathways Analysis (IPA) 7.5.
Results: The BM mononuclear cells showed 764 up-regulated and 1,910 down-regulated genes in RA patients
relative to the OA group. EASE revealed that the gene category response to external stimulus, which included
the gene category immune response, was overrepresented by the up-regulated genes. So too were the gene
categories signal transduction and phosphate metabolism. Down-regulated genes were dominantly classified in
three gene categories: cell proliferation, which included mitotic cell cycle, DNA replication and chromosome
cycle, and DNA metabolism. Most genes in these categories overlapped with each other. IPA analysis showed
that the up-regulated genes in immune response were highly relevant to the antigen presentation pathway and
to interferon signaling. The major histocompatibility complex (MHC) class I molecules, human leukocyte antigen
(HLA)-E, HLA-F, and HLA-G, tapasin (TAP) and TAP binding protein, both of which are involved in peptide
antigen binding and presentation via MHC class I molecules, are depicted in the immune response molecule
networks. Interferon gamma and interleukin 8 were overexpressed and found to play central roles in these
networks.
Conclusions: Abnormal regulatory networks in the immune response and cell cycle categories were identified in
BM mononuclear cells from RA patients, indicating that the BM is pathologically involved in RA.
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Rheumatoid arthritis (RA) is a systemic autoimmune
disease characterized by chronic synovitis that is often
pathogenic and destructive to articular cartilage and
bone. To understand the complex pathogenesis and het-
erogeneous manifestations of autoimmune diseases
including RA, DNA microarray has emerged as a power-
ful tool [1-4]. We have shown in studies investigating
the pathogenesis of juvenile idiopathic arthritis (JIA) and
systemic lupus erythematosus (SLE) that DNA microar-
ray can be even more effective when combined with
bioinformatics techniques such as gene ontology data-
bases and network pathway analysis software [5,6].
In RA pathology, fibroblast-like synoviocyte (FLS) has
been shown to play an essential role in the chronic
inflammation of RA joints [7]. Therefore, a number of
gene expression profiling studies have focused on syno-
vial tissue or FLS to understand the aberrant biological
pathways that contribute to the pathogenesis of RA [1].
Others have focused on peripheral blood mononuclear
cells (PBMC) from RA patients, either by comparing
them with PBMC from healthy individuals or from
patients with other autoimmune diseases [1,3]. Of
greater interest to us is the accumulating evidence sug-
gesting that abnormalities in the bone marrow (BM)
have a significant role in RA inflammation [2,8,9].
The BM contains three types of stem cells: hematopoie-
tic stem cells (HSCs), which produce all the mature blood
lineages for leukocytes, erythrocytes, and platelets;
mesenchymal stem cells, which can differentiate into
osteoblasts, chondrocytes, and adipocytes; and endothelial
stem cells. The proliferations and differentiations of these
heterogeneous cell populations are dependent on the BM
microenvironment and are regulated by highly sophisti-
cated networks, either through cell-cell interactions or
cytokine networks. Indeed, a remarkable elevation in IL6
and IL8 levels in the BM serum from RA patients has
been reported to relate to the synovial proliferation seen
in multiple joints [10]. Therefore, BM cells may be where
the pathogenesis of RA originates, making the study of
their abnormal regulatory networks very important.
In this study, we identify aberrant regulatory networks
in BM cells from RA patients by analyzing differentially
expressed genes based on their gene expression profiles
with those of osteoarthritis (OA) patients. OA patients
were chosen because the OA pathology is relatively well
understood and the BM cells from these patients are far
more readily available than those from healthy subjects.
Materials and methods
Human subjects and ethical considerations
Nine patients (all women, median age 73 years, range
41 to 77 years) with RA satisfying the 1987 revised
diagnostic criteria of the American College of
Rheumatology [11] and 10 patients with OA (all
women, median age 69 years, range 39 to 90 years) ful-
filling American College of Rheumatology criteria for
h i po rk n e eO A[ 1 2 ]w e r ee n r o l l e di nt h ep r e s e n t
study after obtaining their written informed consent.
The study was reviewed and approved by the Ethical
Committee of Wakayama Medical University. BM fluid
was intraoperatively obtained from the nine RA
patients and the 10 OA patients while undergoing
joint arthroplasty. Detailed patient characteristics,
medication usage, including disease-modifying agents
and steroids, and laboratory testing, including rheuma-
toid factor (RF) and C-reactive protein (CRP), of the
nine RA patients are shown in Table 1. None of the 10
OA patients received steroids or disease-modifying
antirheumatic drugs (DMARDs).
GeneChip microarray and data analysis
Patient BM were collected and kept at 4°C. All BM-
derived mononuclear cells (BMMC) were isolated by
using Ficoll-Paque™ Plus (GE Healthcare Biosciences,
Tokyo, Japan) gradient centrifugation according to
the manufacturer’s recommendations. Total RNA
from the BMMCs was extracted by using the RNeasy
Mini Kit (Qiagen, Tokyo, Japan). A 3 μgs a m p l eo f
total RNA was used for DNA microarray analysis by
using GeneChip Human Genome U133 Plus 2.0 Array
(Affymetrix, Santa Clara, CA, USA). Signal values
were obtained according to the manufacturer’s
instructions and normalized by eliminating the high-
est and lowest 2% of the data, respectively. Only data
with present or marginal detection calls were selected
for further analysis. Microarray data have been depos-
ited in NCBIs Gene Expression Omnibus (GEO) and
are accessible through GEO series accession number
[GSE27390].
Gene ontology and network pathway analysis
Genes were identified as differentially expressed if their
mean signal values were at least 50% different between
the RA and OA groups. These genes were functionally
categorized using Expression Analysis Systematic
Explorer (EASE) version 2.0 bioinformatics software
[13]. Interactions among the differentially expressed
genes in each gene category were investigated by using
Ingenuity Pathway Analysis (IPA) version 7.5 [14]. Net-
works generated by less than 10 uploaded genes were
excluded from the analysis.
Statistical analysis
The false-discovery rate was used to determine statisti-
cally significant differences in the mRNA expression
levels between the RA and OA groups. The criterion for
the statistical significance was q < 0.001.
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Gene ontology analysis for differentially expressed genes
in RA and OA patients
DNA microarray analysis revealed that 2,674 genes were
differentially expressed in BMMC from patients with RA
compared with those from patients with OA: 764 out of
the 2,674 genes were up-regulated and the remaining
1,910 genes were down-regulated.
To identify any aberrant biological function in the
BMMC of RA patients, EASE based on the Gene Ontol-
ogy (GO) database, which can classify large gene lists
into functionally related gene groups and rank their
importance, was performed. EASE classified the gene
categories into three GO systems: biological process, cel-
lular component, and molecular function. Up-regulated
and down-regulated genes for the GO system biological
process based on EASE are shown in Tables 2 and 3,
respectively. The EASE score, which is a modified Fish-
er’s exact test, represents the probability that an over-
representation of a certain gene category occurs by
chance. Based on common genes, the gene categories
were further divided into subsets. Each subset of a gene
category was then ordered hierarchically based on the
gene list. Identical gene lists are listed as one gene cate-
gory. The parameter list refers to the total number of
up- or down-regulated genes annotated in the GO sys-
tem (not shown). There were 348 genes in the list for
the 764 up-regulated genes and 733 genes in the list for
the 1,910 down-regulated genes. List hits shows the
number of up- or down-regulated genes that belong to
a respective gene category. The parameter population
reports all genes annotated in the GO system (not
Table 1 Demographic and rheumatoid arthritis disease characteristics
Patient RA disease RF CRP steroid DMARDs
no. duration (years) (Unit/mL) (mg/dL) (mg/day)
1 21 172 3.3 10 MTX 6 mg/week
2 24 99 2.0 5 Bucillamine 100 mg/day, MTX 4 mg/week
3 40 507 3.3 0 Actarit 200 mg/day
4 45 49 0.3 0
5 9 324 2.6 4
6 16 13 1.4 2.5 Bucillamine 100 mg/day
7 2 242 4.4 7.5 Salazosulfapyridine 1000 mg/day, MTX 6 mg/week
8 24 98 0.9 0 MTX 4 mg/week
9 17 40 2.9 5 MTX 6 mg/week
CRP, C-reactive protein; DMARDs, disease-modifying antirheumatic drugs; MTX, methotrexate;
RA, rheumatoid arthritis; RF, rheumatoid factor.
Table 2 Top 15 deviated gene categories of overexpressed genes in rheumatoid arthritis bone marrow compared with
osteoarthritis bone marrow
Gene category List hits Population hits EASE score
(GO biological process) (Total = 348) (Total = 10,937)
response to external stimulus 67 1263 2.52E-05
response to biotic stimulus 61 821 6.47E-10
defense response 57 756 1.62E-09
immune response 56 682 9.89E-11
response to pest/pathogen/parasite 27 444 1.92E-03
antigen processing, endogenous antigen via MHC class I 4 12 5.63E-03
response to stress 37 784 1.57E-02
signal transduction 97 2196 3.43E-04
intracellular signaling cascade 47 761 1.62E-05
protein kinase cascade 12 155 1.04E-02
activation of MAPK 4 16 1.30E-02
phosphate metabolism 33 662 1.13E-02
phosphorylation 28 524 8.90E-03
protein amino acid phosphorylation 26 478 9.74E-03
RNA splicing, via transesterification reactions 8 83 1.61E-02
EASE, Expression Analysis Systematic Explorer software, Version 2.0; Gene Ontology database; GO, gene ontology; MAPK, mitogen activated protein kinase; MHC,
major histocompatibility complex.
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biological process is 10,937. Population hits shows the
number of genes that belong to a respective gene cate-
gory in the system.
EASE of the up-regulated genes identified four major
gene categories: response to external stimulus, signal
transduction, phosphate metabolism, and RNA splicing,
via transesterification reactions (Table 2). Based on
EASE scores, response to biotic stimulus (EASE score:
6.47E-10), defense response (1.62E-09), and immune
response (9.89E-11) were the three most significant gene
categories that corresponded with response to external
stimulus. Fifty-six of the 67 genes in response to exter-
nal stimulus belonged to immune response, which had
the lowest EASE score (9.89E-11). The genes in signal
transduction corresponded to intracellular signaling cas-
cade, protein kinase cascade, and activation of mitogen-
activated phosphate kinase (MAPK). Twenty-six of the
33 genes in phosphate metabolism belonged to protein
amino acid phosphorylation. Finally, there were eight
genes in RNA splicing, via transesterification reactions.
EASE for the down-regulated genes identified three
major gene categories: cell proliferation, DNA replica-
tion and chromosome cycle, and DNA metabolism
(Table 3). The down-regulated genes were predomi-
nantly classified into cell cycle (EASE score: 1.06E-26),
mitotic cell cycle (2.78E-37), M phase (3.98E-19),
nuclear division (4.40E-19), and mitosis (7.91E-21).
These gene categories were arranged hierarchically in
cell proliferation, which contains 139 genes. Genes
related to regulation of cell cycle also belonged to cell
proliferation with significant probability (1.83E-11).
Most of the genes in the three major gene categories
overlapped.
Up-regulated genes in the category immune response
and their corresponding network pathway analysis
T h eg e n ec a t e g o r yi m m u n er e s p o n s ef o ru p - r e g u l a t e d
genes and mitotic cell cycle for down-regulated genes
had the lowest EASE scores, respectively. The relations
among the 56 up-regulated genes and the 97 down-
regulated genes in these two gene categories were
further analyzed by IPA.
IPA analysis revealed that the up-regulated genes in
immune response were highly relevant to the antigen
presentation pathway and to interferon (IFN) signaling.
There were four networks represented by the 56 up-
regulated genes (Figure 1). The first network (Figure 1a)
has a T-cell receptor (TCR), IFN-alpha, and nuclear fac-
tor kappa B (NFkB) complex at its center. Several cyto-
kine receptors such as IL2 receptor (IL2R), IL4R, and
IL7R are depicted in this network. A cluster of human
leukocyte antigens (HLA), HLA-E, HLA-F, and HLA-G,
which are all major histocompatibility complex (MHC)
class I molecules, tapasin (TAP), and TAP binding pro-
tein (TAPBP) are also represented in this network. The
second network (Figure 1b) has the p38 MAPK com-
plex, MAPK14, IL8, and myeloid differentiation primary
response gene 88 (MyD88) at its center. Proinflamma-
tory cytokines such as IL1 and IL12 (complex), and type
I IFN are also found in the network although neither
the expression of IFNa nor IFNb are significantly up-
regulated. FCgR3A, CXCR4, and three IFN-inducible
(IFI) molecules, IFITM1, IFITM3, and IFI16 are found
Table 3 Top 15 deviated functional categories of underexpressed genes in rheumatoid arthritis bone marrow
compared with osteoarthritis bone marrow
Gene category List hits Population hits EASE score
(GO biological process) (Total = 733) (Total = 10,937)
cell proliferation 139 1036 4.05E-16
cell cycle 127 690 1.06E-26
mitotic cell cycle 97 329 2.78E-37
M phase 48 157 3.98E-19
nuclear division 47 151 4.40E-19
mitosis 44 121 7.91E-21
regulation of mitosis 11 26 3.37E-06
regulation of cell cycle 64 384 1.83E-11
cell cycle checkpoint 15 35 1.98E-08
cytokinesis 26 95 1.83E-09
DNA replication and chromosome cycle 52 186 8.28E-19
DNA replication 40 146 2.96E-14
DNA dependent DNA replication 23 75 1.86E-09
DNA metabolism 85 517 1.02E-14
nucleocytoplasmic transport 21 97 5.06E-06
EASE, Expression Analysis Systematic Explorer software, Version 2.0; Gene Ontology database; GO, gene ontology.
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Page 4 of 9Figure 1 Network pathway analysis of up-regulated genes in the gene category immune response. (a to d) Four different networks
constructed by the 56 up-regulated genes. Genes and gene products are represented as individual nodes whose shapes represent the
functional class of the gene products. The biologic relation between two nodes is represented as an edge (line). All edges are supported by at
least one reference from the Ingenuity Pathways Knowledge Base (IPKB). Genes in colored nodes are overexpressed. Genes in uncolored nodes
are not, but are depicted by the computationally generated networks on the basis of evidence stored in the IPKB indicating a strong biologic
relevance to that network.
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network is found to have IFNg play a central role (Fig-
ure 1c). The proteasomes PSMB8 and PSMB9, two C-
type lectin family molecules, CLEC5A and CLEC4E,
IFI35, and arachidonate 5-lipoxygenase-activating pro-
tein (ALOX5AP) are depicted in this network. The
fourth and final network has hepatocyte nuclear factor
(HNF) 4A at its center. HNF4A is a nuclear transcrip-
tion factor that binds DNA as a homodimer. Besides the
regulation of transcription, it is also involved in the reg-
ulation of the lipid metabolic process, blood coagulation,
and negative regulation of cell growth. The up-regulated
molecules CD46 and CD53 are also found in this net-
work, whereas IL6 is found to be involved in its
regulation.
Down-regulated genes in the category mitotic cell cycle
and their corresponding network pathway analysis
IPA found down-regulated molecules to significantly
a f f e c tt h er o l eo fp o l o - l i k ek i n a s ei nm i t o s i s ,t h er o l eo f
CHK protein in cell cycle checkpoint control, and affect
pyrimidine metabolism, and ataxia telangiectasia
mutated (ATM) signaling. There were four networks
constructed by the 97 down-regulated genes in the
mitotic cell cycle (Figure 2). Several cyclins (CCN), cell
division cycle (CDC)-related molecules, and cyclin-
dependent kinase (CDK)-related molecules played cen-
tral roles in the first three networks. CCNA2, CCNE2,
CDC6, a group of polymerase (POL) molecules includ-
ing POLA1, POLE2, POLE3, and POLQ, six mini-chro-
mosome maintenance (MCM) complex component
genes, and three origin recognition complex (ORC) sub-
unit genes are depicted in the first network (Figure 2a).
CCNB1 and CDC2 are found at the center of the second
network (Figure 2b). CDC27, CDC25A, CCNF, WEE1,
topoisomerase II a (TOP2A), three structural mainte-
nance of chromosome (SMC)-related molecules, and
two kinesin family member (KIF)-related molecules are
also represented in the second network. CCNE1, CDK
inhibitor 1B, and histones are involved in the third regu-
latory network (Figure 2c). In the last network, although
the expression of IL6, TP53, and HNF4A were not dif-
ferentially expressed, they are all included in this net-
work and play key roles in its regulation (Figure 2d).
Discussion
It is commonly known that autoimmunity plays a pivo-
tal role in the pathology of RA. However, the exact
etiology and pathogenesis are poorly understood. Our
work, comparing the gene expression profiles of BMMC
between RA patients and OA patients by microarray
technology and gene ontology analysis, found abnormal
immune responses in BMMC. This agrees with accumu-
lating evidence indicating that abnormalities in BM cells
may contribute to the pathogenesis of RA [9]. To our
knowledge, ours is the first report to combine DNA
microarray with bioinformatics for describing gene
expression profiles from RA BM cells and for revealing
abnormal networks involving immune response- and
cell cycle-related molecules in those cells.
Several reports have shown that peripheral blood from
SLE patients has remarkably homogenous gene expres-
sion patterns and an overexpression of IFI genes
[6,15-17]. The IFN signaling pathway is thought to play
an important role in the pathogenesis of SLE. There is
also one report of genomically profiled peripheral blood
cells from 35 RA patients and 15 healthy controls that
found a type I IFN signature in a subpopulation of RA
patients [3]. Here, we show that the IFN signaling path-
way elevates in the BM cellular network pathway of RA
patients similar to that in the peripheral blood of SLE
patients, although to a lesser degree. The different IFN
effects on RA and SLE may be because cytokines are
pleiotropic in their biological activities and that they
interact with each other in highly sophisticated net-
works. Along these lines, the effects of IFNb treatment
on arthritis were reviewed several years ago. An open,
phase I study conducted on 12 patients with active RA
and another pilot study performed on six children with
juvenile RA have both shown that IFNb treatment is in
general well tolerated and leads to improvement [18].
However, two other case reports claim RA can develop
after the onset of IFNb treatment in patients with multi-
ple sclerosis [18]. These suggest IFNb therapy cannot be
used universally to combat the development of arthritis.
Meanwhile, our finding that the MHC class I mole-
cules HLA-E, HLA-F, and HLA-G, TAP, and TAPBP
were all overexpressed in the BM cells of RA patients is
also novel. All these genes relate to the antigen presen-
tation pathway. For example, up-regulation of HLA-E is
considered a potential marker for cancer. Additionally,
its expression can confer resistance to NK cell-mediated
lysis [19,20]. HLA-F has been recently reported to be a
surface marker for activated lymphocytes [21], while
HLA-G has its highest expression during pregnancy and
is thought to play a key role in modulating immune tol-
erance [22]. There is a recently published study by Pri-
gione et al. that reports a lower concentration of soluble
HLA-G in sera may predispose to JIA and soluble HLA-
E concentration in synovial f l u i dc o r r e l a t e dw i t ht h e
number of affected joints [23]. Nevertheless, the func-
tions of these molecules in autoimmunity are still
unclear and debated. In addition, we found TCR, IFNa,
NFkB, p38MAPK, IL8, MyD88, and IFNg play central
roles in the immunoregulatory networks of BMMC in
R A .E x c e p tf o rN F k B ,w ef o u n da l lt h e s eg e n e st ob e
overexpressed. MyD88, the Toll/IL-1 receptor (TIR)-
containing adaptor, is used by almost all Toll-like
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that results in the activation of NFkB to express cytokine
genes involved in inflammation, as well as IFN-inducible
genes [24,25]. It is possible the up-regulation of MyD88
has a significant role on the aberrant immune response
network seen in BMMC from RA patients. However, our
data do not show a complementary up-regulation of TLRs,
nor do they confirm that the up-regulation of MyD88 was
caused by TLRs. It is interesting that Nagata reported up-
regulation of IFN-inducible genes in DNase II-deficient
mice, which develop a chronic polyarthritis resembling
human RA, and they further found no involvement of a
TLR system in the IFNb gene activation in DNase II
-/-
embryos [26]. Kawane et al. also recently showed that
when BM cells from the DNase II-deficient mice were
transferred to the wild-type mice, they developed arthritis
[27]. Although the mechanisms of arthritis pathogenesis
may be different between mice and humans, these mouse-
model data do provide supportive evidence to our report.
Another interesting observation is that underexpressed
genes were dominantly related to cell cycle and DNA
metabolism. We are the first to report the suppression
of cell cycle and DNA metabolism in BM cells from RA
patients. Initially, there appear to be several possible
Figure 2 Network pathway analysis of down-regulated genes in the gene category mitotic cell cycle. (a to d) Four separated networks
constructed by the down-regulated genes.
Lee et al. Arthritis Research & Therapy 2011, 13:R89
http://arthritis-research.com/content/13/3/R89
Page 7 of 9mechanisms that can explain this result. One is a thera-
peutic effect caused by MTX, as MTX acts by inhibiting
the metabolism of folic acid, which is needed for the de
novo synthesis of the nucleoside thymidine required for
DNA synthesis. However, subsequent analysis showed
MTX treatment does not correlate with the down-regu-
lated gene expressions (data not shown). Alternatively,
we considered the fact the BMMC samples in this study
were isolated by using Ficoll-Paque, which may cause
nucleated erythroblasts to be miscible in mononuclear
cell proportions and thus affect cell cycle. Finally, a high
concentration of serum IL6 in BM has been reported in
RA patients [10]. This is important because IL6 induces
the secretion of hepcidin, a humoral factor regulating
intestinal iron absorption and iron storage in micro-
phages [28,29]. Hepcidin can contribute to low serum
iron levels if up-regulated, which can then suppress ery-
throblast differentiation and proliferation in BM, as iron
is a requisite element for this process. Furthermore, Col-
megna et al. reported a defective proliferative capacity
by peripheral blood hematopoietic progenitor cells from
RA patients [30]. They further showed that ATM defi-
ciency in RA patients disrupts DNA repair and renders
T cells sensitive to apoptosis [31]. Together with their
results and our finding that the ATM signaling pathway
is repressed in the immunoregulatory networks of
BMMC, we suggest that in RA patients, impairments in
their immune response cells originally occur in the BM.
However, more work is needed on a number of issues
including why cell cycle and DNA metabolism were
suppressed in the BM, how this suppression relates to
RA, and whether defective BM cells relate to activated-
immune responses in RA patients.
According to our unpublished data, the genes
expressed in the peripheral blood cells of RA patients
that correspond to cell cycle and DNA metabolism were
not down-regulated as observed in BM cells, but the
d o w n - r e g u l a t i o nf o rt h o s ei nR N Am e t a b o l i s m -o r
translation-related genes were found. As all mature
blood lineages in peripheral blood are produced from
HSCs in the BM, the s abnormality in immune response
and suppression of cell cycle in BM may contribute to
the pathogenesis of RA.
Conclusions
BM cells from RA patients had abnormal functional net-
works in immune response and cell cycle when compared
with the BM cells from OA patients. Our results suggest
that the overexpression of genes that take part in the anti-
gen presentation pathway and IFN signaling contribute to
the pathogenesis of RA. Our results also suggest that the
underexpression of genes relating to cell cycle in the BM
may be a potential pathogenic factor for RA.
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